降低服用甲福林的糖尿病患者中嗅觉功能障碍的患病率
Varun Vohra1, Anirudh Saraswathula1, Vidyulata Kamath2
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
International forum of allergy & rhinology
|July 7, 2023
概括
甲胺可能会保护糖尿病患者的嗅觉. 这种常见的糖尿病药物似乎可以减少嗅觉功能障碍,这表明除了血糖控制之外的好处.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 眼科医生 眼科 眼科
背景情况:
- 糖尿病患者经常经历嗅觉功能障碍 (OD).
- 糖尿病中OD背后的机制尚未完全理解.
- 血糖控制是管理糖尿病并发症的主要重点.
研究的目的:
- 研究糖尿病患者的甲福明使用与嗅觉功能障碍之间的关联.
- 探索甲胺对嗅觉功能的潜在神经保护作用.
主要方法:
- 对患者数据的回顾性分析.
- 在甲福明使用者和非使用者之间对嗅觉功能指标的比较.
- 统计分析用于控制混因素.
主要成果:
- 甲胺治疗与嗅觉功能障碍的患病率较低显著相关.
- 与对照组相比,接受甲福明的患者的嗅觉测试得分更好.
- 这种关联在调整年龄,糖尿病持续时间和血糖控制后仍然存在.
结论:
- 梅特福林的使用与糖尿病患者的嗅觉功能障碍减少有关.
- 甲福明可以为嗅觉功能提供保护性益处,独立于其降糖效应.
- 需要进一步的研究来阐明甲胺在嗅觉通路上的直接机制.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
238
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
238
Diabetes: Symptoms, Diagnosis, and Complications
603
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
603
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Carbohydrate Metabolism
11.3K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.3K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214


